Why inhibit only one KRAS mutant when you can inhibit multiple KRAS alterations at the same time. Our pan-KRAS inhibitor paper is out. nature.com/articles/s4158…

Happy to share our recently published article. Addition of metformin to chemotherapy doesn’t improve outcomes in advanced NSCLC. Does it have meaningful anti cancer effect with other combinations or in other settings? It remains unanswered. rdcu.be/ddzb6

Proud moment for us at AIIMS, New Delhi 🇮🇳 Many congratulations to Atul Batra @TuttsAkhil and team for this fantastic practice changing study!

Lots of hard work by @TuttsAkhil put into this.

#IndiaAtAsco #ASCO23 Me presenting our study on dexamethasone free antiemetic regimen

I have tweeted more than 500 times about current information in oncology. My tweet below was the most retweeted tweet in the scientific community. The topic of the tweet is the success of topical diclofenac in reducing HFS. I hope the pharmaceutical industry gets the message.

Good bye to CT Scan,MRI, Xray. Cardiovascular events can be predicted by eye scan. Doctors can now get clear view of what is inside the body of a patient. Sundar Pichai, Google AI

Wow ! Artificial Intelligence in Molecular Medicine. How can we use #AI to move #PrecisionMedicine forwards NEJM nejm.org/doi/full/10.10…

A new study highlights the utility of circulating tumour cells as a disease progression-monitoring tool in recurrent head and neck squamous cell carcinoma patients Annie K Baa Raja Pramanik atul ecancer.org/en/journal/art…

A highly recommended international workshop on biomedical research methodology. In this workshop, faculty members work harder than participants. Link 👇 #credo Pramesh CS

Congratulations Professor Navneet Singh for your exemplary work Navneet Singh and for the Clifton F. Mountain Lectureship Award for Staging ! 🌺🌺🌺 A proud moment for us in India ! 👏👏👏 #WCLC2023 #LungCancerIndia

A huge shoutout to Navneet Singh for the #WCLC23 lectureship award for staging IASLC

Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial | Journal of Clinical Oncology Simple solutions to seemingly complex problems👇 Journal of Clinical Oncology #ASCO23 ascopubs.org/doi/10.1200/JC…

D-TORCH full paper out in Journal of Clinical Oncology 👯‍♂️ Breast or GI cancer Capecitabine treatment N=263 👉Diclofenac gel or Placebo 🎯G2/3 HFS: 3.8% v 15.0% 👉Less frequent dose reduction 👉Better QoL @TuttsAkhil Atul Sharma Sameer Bakshi ascopubs.org/doi/10.1200/JC…

Progression-free survival and overall survival benefits of adding chemotherapy to gefitinib were sustained at 5 years, confirming earlier results reported at median follow-up of 17 months. ja.ma/3Jw1Ox0

Integrating Artificial Intelligence-Driven Wearable Technology in Oncology Decision-Making: A Narrative Review karger.com/ocl/article/do…

Low dose versus standard dose pembrolizumab for treatment of stage IV stage NSCLC: Results of the pre-planned interim analysis of the NVALT-30 clinical trial ❓Will this be the end of the discussion? Thoughts? #ESMO24 #LCSM

Nobel Prize is NOT about h-index or citations. It is about the emergence of big new fields. So many posts discuss Nobel awardees. And so many misunderstand the Nobel Prize. 📍 A bit of clarification from my side: 1⃣ Nobel Prize is NOT about how useful your work is. It’s about

Online Now: The hallmarks of cancer immune evasion dlvr.it/TFFy1H

"Young Onset Lung Cancer in India: Insights into Clinical, Demographic, and Genomic Profiles" - Clinical Lung Cancer clinical-lung-cancer.com/article/S1525-…. Happy to share our recent paper highlighting the profile of young onset LC which is otherwise rare.